Lung Cancer is the leading cause of cancer deaths around the world, causing more deaths than prostate, breast and colon cancer combined.¹ Only 18.5 percent of patients will survive five or more years after being diagnosed with lung cancer.²
Reinforcing the National Lung Cancer Screening Trail’s (NLST)³, the Nelson study provided promising new results that annual screening of high risk patients using low dose CT had a 26 percent mortality reduction in the male trial.^4,5 GE Healthcare provides high quality CT scanners for the new low dose lung cancer screening option.⁶

In the United States, about 23,820 malignant tumors of the brain or spinal cord will be diagnosed in 2019.¹ With the technological advances in the technology field, brain tumor imaging has become an essential component in managing the patients across the care pathway.

One in seven men will be diagnosed with prostate cancer,¹ with 1.2 million new cases in 2018.² According to the American Cancer Society the overall 5-year survival rate is 99 percent for all stages of prostate cancer, however when diagnosed at stage IVB, the 5-year survival rate drops significantly to 29 percent.³

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year. According to the WHO, it is estimated that 627,000 women died from breast cancer in 2018 which represents 15 percent of all cancer deaths among women.¹

The global burden of colorectal cancer (CRC) is expected to increase by 60 percent to more than 2.2 million new cases and 1.1 million deaths by 2030.¹ Colorectal cancer is the third most common cancer diagnosed in both men and women in the United States.

In 2016, 467,000 new cases of leukemia and 310,000 deaths were reported. One in 118 men will develop the disease compared with one in 194 women. The main contributors to this increase were population growth with 12 percent, population aging with 10 percent, and an increase in age-specific incidence rates with 3 percent.¹

Liver cancer is the fifth most common cancer, accounting for 8.2 percent of all cancer deaths worldwide.¹ The incidence is rising across all continents including in the United States. A study published in JAMA Oncology, December 2017 found the incidence of liver cancer increased by 75 percent worldwide between 1990 and 2015.² Effective surveillance programs with imaging could offer early diagnosis and provide an opportunity for better treatment options.

Lung Cancer is the leading cause of cancer deaths around the world, causing more deaths than prostate, breast and colon cancer combined.¹ Only 18.5 percent of patients will survive five or more years after being diagnosed with lung cancer.²
Reinforcing the National Lung Cancer Screening Trail’s (NLST)³, the Nelson study provided promising new results that annual screening of high risk patients using low dose CT had a 26 percent mortality reduction in the male trial.^4,5 GE Healthcare provides high quality CT scanners for the new low dose lung cancer screening option.⁶

In the United States, about 23,820 malignant tumors of the brain or spinal cord will be diagnosed in 2019.¹ With the technological advances in the technology field, brain tumor imaging has become an essential component in managing the patients across the care pathway.

One in seven men will be diagnosed with prostate cancer,¹ with 1.2 million new cases in 2018.² According to the American Cancer Society the overall 5-year survival rate is 99 percent for all stages of prostate cancer, however when diagnosed at stage IVB, the 5-year survival rate drops significantly to 29 percent.³